Curis Q4 2022 Earnings Report
Key Takeaways
Curis reported its Q4 2022 financial results, with a net loss of $11.3 million, or $0.12 per share. The company also announced the completion of enrollment for the additional patients requested by the FDA in the TakeAim Leukemia study.
Completed enrollment of 9 additional patients in TakeAim Leukemia study ahead of schedule.
Presented positive updated clinical data from the Phase 1a dose escalation study of emavusertib at the ASH Meeting.
Expects to include data from the 9 additional patients in discussions with FDA in Q3.
Cash, cash equivalents and investments totaled $85.6 million as of December 31, 2022, expected to maintain planned operations into 2025.
Curis
Curis
Curis Revenue by Segment
Forward Guidance
Curis expects to discuss data from additional patients with the FDA in Q3 to determine RP2D and resolve the partial clinical hold. Existing cash, cash equivalents and investments are expected to enable planned operations into 2025.